| Course | NR 586NP Population Health and Epidemiology for Advanced Nursing Practice |
|---|---|
| Week | 6 |
| Paper type | Health disparity analysis |
| Length | About 1,170 words, 5 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, nurse practitioner core |
| Updated | October 2026 |
Free sample paper for NR 586NP Week 6
Health Disparity Analysis: Hepatitis C Treatment Within Six Months of Diagnosis for Medicaid and Privately Insured Patients at a Rural Health Center, 2022 and 2025
Student Name
College of Nursing, Chamberlain University
NR 586NP: Population Health and Epidemiology for Advanced Nursing Practice
Instructor Name
Month Day, Year
Health Disparity Analysis: Hepatitis C Treatment Within Six Months of Diagnosis for Medicaid and Privately Insured Patients at a Rural Health Center, 2022 and 2025
The Outcome and the Groups
The outcome is starting direct-acting antiviral treatment within six months of a positive hepatitis C RNA result at the Hollis County health center. The groups are patients covered by Medicaid at the time of diagnosis and patients with private insurance. Uninsured patients are reported but not used as the comparison, because there were only 15 of them in 2025.
The Comparison Is the Claim
The reference group is patients with private insurance. I chose it because private insurance at this health center does not require prior authorization for treatment from the two largest insurers, so it shows what happens when the main access barrier is absent. The alternative, comparing Medicaid with all other patients combined, would mix the privately insured with the uninsured, who face larger barriers than either group, and would make the gap look smaller than it is.
Both Distances
| Year | Medicaid: started / diagnosed | Private: started / diagnosed | Difference (points) | Ratio |
|---|---|---|---|---|
| 2022 | 22 / 70 (31.4%) | 14 / 19 (73.7%) | 42.3 | 0.43 |
| 2025 | 38 / 89 (42.7%) | 17 / 24 (70.8%) | 28.1 | 0.60 |
In 2025 the difference was 28 percentage points: of every 100 patients diagnosed, 28 more privately insured patients than Medicaid patients started treatment within six months. The ratio was 0.60: Medicaid patients started treatment at 60% of the rate of privately insured patients. Both are needed. The difference shows the size of the gap in patients; the ratio shows how unequal the chances are. With 89 Medicaid patients diagnosed, a 28-point gap means about 25 patients who would have started treatment if their chance matched the reference group's.
Nationally, a study of insured adults diagnosed with hepatitis C found that only about a third started treatment within a year, and those with Medicaid were less likely to be treated than those with private insurance (Thompson et al., 2022). The pattern at the health center matches that finding.
Which Group Moved
The gap narrowed between 2022 and 2025, from 42 points to 28 points. The question weak analyses skip is why. The Medicaid group's share rose by 11.3 points, from 31.4% to 42.7%. The private group's share fell by 2.9 points, from 73.7% to 70.8%. Of the 14.2-point narrowing, about 11 points came from Medicaid patients doing better and about 3 from privately insured patients doing slightly worse. The narrowing is mostly real improvement for the disadvantaged group.
What changed for Medicaid patients: in 2023 the state Medicaid program dropped its requirement for documented abstinence from drugs and alcohol before treatment, and removed the requirement that a specialist prescribe. Prior authorization remains, with a fibrosis test required.
Artifact Before Attribution
Before attributing the gap to insurance, three artifacts need checking.
Small numbers. The private group has only 24 patients in 2025. Its 70.8% could plausibly be anywhere from about 50% to 87%. The gap is unlikely to disappear within that range, but its exact size is uncertain.
Treatment outside the health center. Some patients may start treatment at another clinic and not be counted. If Medicaid patients more often move between clinics, their rate could be undercounted. I checked the state's prescription monitoring data where available; four Medicaid patients and one private patient had started treatment elsewhere. Adding them raises the Medicaid share to 47.2% and the private share to 75.0%, a difference of 27.8 points. The gap remains.
Insurance changes. Insurance was recorded at diagnosis. A patient who lost Medicaid and became uninsured after diagnosis is counted as Medicaid. That would make the Medicaid group's rate look worse if losing coverage blocked treatment, which is itself part of the disparity rather than an error.
Mechanisms
The gap is best explained by access and delivered care, not by the patients. Medicaid patients face a prior authorization process that requires a fibrosis test, which at the health center means a liver scan at the hospital 70 miles away or a blood-based score, and a form that takes staff time. The median time from diagnosis to approval for Medicaid patients was 19 days, against 4 days for private patients' prescriptions to be filled. Each step is a chance for a patient without a car or a stable phone number to drop out. Medicaid patients at the health center are also more likely to be unstably housed and to be actively using drugs, which affects whether they keep appointments, but those are exposures and circumstances, not choices that explain the whole gap.
A Category Is Not a Cause
Medicaid coverage does not cause anyone to go untreated. It marks a group that meets a specific process, prior authorization with a fibrosis requirement, and that is more likely to be poor and to lack transport. Writing that Medicaid patients "are less adherent" would explain the gap with a trait of the people in it. The data point instead to steps in the process that the health center and the state can change. The analysis should therefore lead to process changes, not to education aimed at Medicaid patients.
Where the Gap Opens
Breaking the six-month period into steps shows where Medicaid patients are lost. Of 89 Medicaid patients with current infection, 67 saw a nurse practitioner (75%), against 22 of 24 privately insured patients (92%). Of those seen, 38 of 67 Medicaid patients started treatment (57%), against 17 of 22 private patients (77%). The gap opens at both steps, but the larger loss is after the visit, during the authorization period. That points the intervention at the steps after the nurse practitioner visit, and at getting more Medicaid patients to the visit in the first place.
How This Fits the National Recommendation
The national recommendation to screen every adult (Schillie et al., 2020) has increased the number of people diagnosed, which makes the step from diagnosis to treatment more important. A screening program that widens diagnosis without closing treatment gaps could, in effect, widen disparities in who is cured, even as it narrows disparities in who is diagnosed. Friis and Sellers (2021) note that disparities can arise at any stage of care, and this analysis locates them at the stage after diagnosis.
What Would Close More of the Gap
If Medicaid patients started treatment at the private group's rate, about 25 more patients a year would begin treatment. The next week's plan will target the steps between diagnosis and the first prescription.
Limits
The analysis uses one health center's data and small numbers. Race and ethnicity were not analyzed because more than 95% of the health center's patients are white, so comparisons would rest on too few patients.
References
Friis, R. H., & Sellers, T. A. (2021). Epidemiology for public health practice (6th ed.). Jones & Bartlett Learning.
Schillie, S., Wester, C., Osborne, M., Wesolowski, L., & Ryerson, A. B. (2020). CDC recommendations for hepatitis C screening among adults: United States, 2020. MMWR Recommendations and Reports, 69(2), 1-17. https://doi.org/10.15585/mmwr.rr6902a1
Thompson, W. W., Symum, H., Sandul, A., Gupta, N., Patel, P., Nelson, N., Mermin, J., & Wester, C. (2022). Vital signs: Hepatitis C treatment among insured adults: United States, 2019-2020. MMWR. Morbidity and Mortality Weekly Report, 71(32), 1011-1017. https://doi.org/10.15585/mmwr.mm7132e1
What the NR 586NP Week 6 assignment asks for
The Week 6 analysis fixes on one outcome and one group and holds them. Name and defend the reference group early, because a gap measured against a flattering comparison is a choice dressed as a finding. Report both the difference between rates and their ratio. Follow the trend and answer directly whether the gap narrowed because the disadvantaged group improved or the advantaged group fell back. Check for artifacts before attributing the gap. Then argue mechanisms through exposure, access and care delivered. Most rubrics mark down a gap explained by the habits of the people in it, a reference group chosen to exaggerate or hide the gap, and a category treated as a cause.
How the NR 586NP Week 6 example is put together
The sample's outcome is treatment within six months of a positive RNA result. Privately insured patients are the reference, chosen because their main insurers require no prior authorization, with the rejected alternative explained. A table gives both years, both groups, the difference and the ratio. A section shows the 14-point narrowing came mostly from Medicaid patients improving after a state rule change. Small numbers, treatment elsewhere and insurance changes are checked. A step-by-step breakdown shows where patients are lost. Mechanisms center on prior authorization, a fibrosis test 70 miles away and transport, and the paper explains why insurance marks a process rather than causing the gap.
Where the points sit in the NR 586NP Week 6 rubric
The most expensive move is explaining a gap by the habits of the people inside it, and this analysis explicitly rejects adherence as the explanation. A reference group chosen to make the gap look large or small costs the next share, so the choice of private insurance is defended against an alternative. Reporting one measure only can mislead, and both the difference and the ratio appear. Failing to say which group moved loses a row, while this paper splits the narrowing into its parts. Checking artifacts before attribution earns credit. Treating a demographic or insurance category as a mechanism loses the last marks, and this paper names the processes behind the category.
NR 586NP Week 6 help from the desk
Weak NR 586NP Week 6 analyses explain a gap by culture, compliance or health literacy without examining access. Others pick a comparison group without saying why. Many report only a ratio or only a difference. Few say whether the gap narrowed because one group improved or the other got worse. Artifacts such as small numbers or missing data are often ignored. Choose your reference group and defend it, report both measures, split the trend and check for artifacts before you explain. Then look for processes, not traits. If your gap differs, send the counts for both groups, and a sample analysis can measure and explain it the same way.
Get a NR 586NP Week 6 example written to your instructions
Send the prompt your classroom published, the rubric and the outcome or group you have chosen, and a custom example analysis is built to those choices and comes back within 24-48h, free the first time. If the reference group is left up to you, say so and the example selects one and defends it.
More NR 586NP papers and MSN samples
- NR 586NP Week 1: From Case to Population Post
- NR 586NP Week 2: Community Profile
- NR 586NP Week 3: Rate Calculation Write-Up
- NR 586NP Week 4: Surveillance Data Review
- NR 586NP Week 5: Screening Program Appraisal
- NR 586NP Week 7: Population Intervention Plan
- NR 586NP Week 8: Policy Brief
- NR 507 Week 6: Case Study Analysis
- NR 585NP Week 6: Evidence Synthesis
- NR 509 Week 6: SOAP Note
- NR 584NP Week 6: Improvement Proposal
NR 586NP Week 6 questions, answered
What separates a disparity from a difference?
A difference is any gap between two groups. A disparity is one that is systematic, avoidable and tied to social position rather than to biology or chance. That distinction has to be argued rather than asserted, usually by showing the gap persists once obvious explanations are examined and by pointing to a mechanism that could in principle be changed.
Which reference group should be used?
One that makes the comparison meaningful and that you can defend in a sentence. The common defensible choices are the population as a whole, the group with the best observed rate, or a published benchmark. What loses marks is switching references between measures, or choosing one silently. Say which you used, say why, and note how the picture would shift under another.
How much of the paper should be causes?
Enough that the gap is explained rather than displayed. Descriptive work fills a surprising share of weak drafts, tables and percentages arriving one after another with no argument about why the distance exists at all. The graded weight sits in the reasoning, particularly in ordering candidate mechanisms by the strength of the evidence behind each one.
Where can I find a free NR 586NP Week 6 sample paper?
The full disparity analysis of hepatitis C treatment by insurance at a rural health center, with both measures and the artifact checks, is published on this page.
Which group moved in the NR 586NP Week 6 analysis?
Mostly the Medicaid group: its treatment share rose by 11.3 points while the private group's fell by 2.9, so most of the narrowing was real improvement.